药学服务对冠心病患者PCI术后预后的影响

Effect of pharmaceutical care on cardiac rehabilitation after PCI in patients with coronary heart disease

目的研究药学服务对冠心病患者首次经皮冠状动脉介入治疗(PCI)术后预后的影响。方法选取2020年在泰州市人民医院确诊为冠心病并首次行PCI的患者100例,随机分成两组,对照组和干预组各50例。对照组采用常规的治疗和护理措施;干预组以优化药物治疗方案、药学监护、用药教育、健康宣教、定期药师门诊随访为主要内容。分别比较半年后和1年后两组患者再住院率、不良心脏事件发生率(再发心绞痛、非致死性心肌梗死)、再次血运重建情况,比较两组危险因素如吸烟、血压、血糖、血脂等控制情况、药物知晓情况、患者服药依从性。结果半年后,干预组患者对药物的知晓率明显高于对照组;1年后,干预组患者心血管临床终点事件的发生率明显低于对照组,冠心病危险因素(吸烟、血糖、血压、血脂)控制情况、患者服药依从性与药物知晓情况显著优于对照组,组间差异有统计学意义(P<0.05)。结论实施药学干预可以有效降低PCI术后的冠心病患者术后不良心脏事件发生率,提高服药依从性,控制危险因素,改善预后。

Objective To investigate the effect of pharmaceutical care on the prognosis of patients with coronary heart disease after first percutaneous coronary intervention(PCI).Methods 100 patients with coronary heart disease clinically diagnosed in Taizhou People's Hospital and undergoing PCI for the first time in the whole year of 2020 were randomly divided into two groups,50 cases in the control group and 50 cases in the intervention group.The control group was treated with routine treatment and nursing measures;The main contents of intervention group were drug treatment plan,pharmaceutical care,medication education,health education and regular outpatient follow-up of pharmacists.The rehospitalization rate,incidence of adverse cardiac events(recurrent angina,nonfatal myocardial infarction)and revascularization were compared between the two groups after half a year and one year.The risk factors such as smoking,blood pressure,blood glucose,blood lipid control,drug awareness and compliance were compared between the two groups.Results Six months after PCI,the drug awareness rate in the intervention group increased significantly.One year after surgery,the incidence of adverse cardiac events in the intervention group was significantly lower than that in the control group,the control of risk factors(smoking,blood glucose,blood pressure,blood Lipid),compliance and drug awareness in the intervention group were significantly better than those in the control group(P<0.05).Conclusion Pharmaceutical intervention on patients with coronary heart disease after PCI can effectively reduce the incidence of adverse cardiac events,improve compliance with medication,control risk factors,improve the quality of prognosis.